A First-in-Class, Non-Azole, Fungicidal Treatment for Women with Vulvovaginal Candidiasis – BREXAFEMME (R) (ibrexafungerp tablets)

Description: This webinar will explore the unmet needs of VVC, VVC epidemiology, and burden and provide a clinical overview of BREXAFEMME. Please click here for additional information.

Following this webinar attendees will have a full understanding of:

1) The prevalence of VVC, epidemiology, clinical symptoms, associated economic burden and broad range of VVC patients that are under served:
2) Brexafemme clinical overview, fungicidal mechanism of action, adverse event profile, dosing and administration.

Target Audience: Providers: obstetrician-gynecologists, advanced registered nurse practitioners, physician assistants, midwives, primary care physicians
Speaker: Peter A. Khamvongsa, MD, Associate Professor, Division of Obstetrics and Gynecology, Florida International University College of Medicine, President and Chief Medical Officer, Department of Urogynecology and Minimally Invasive Surgery
Miami Institute for Women’s Health, Miami, FL
Date: Thursday June 16, 2022
Time: 1-2 PM ET
Virtual Platform: Go To Webinar
Fee: $0
CME/CE: 0 hr

IMPORTANT: There is a 2 step registration process -
After registering on this site, you will receive a confirmation email with instructions to register with GoToWebinar to receive your logon instructions and calendar reminder. If you don't receive confirmation email...check your spam/junk folder.

This webinar is sponsored by: